Immune Resolution After Staphylococcus Aureus Bacteremia
NCT ID: NCT01879761
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
102 participants
OBSERVATIONAL
2013-06-30
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds
NCT01551667
Human Immunity Against Staphylococcus Aureus Skin Infection
NCT02262819
Virulence Determinants in S Aureus Bacteremia
NCT00319826
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
NCT00622882
Staphylococcus Aureus Caught in Action at the Site of Infection
NCT04781569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immunosuppressed
Immunosuppressed includes patients with any one of the following:
1. a diagnosis of a hematological malignancy
2. a diagnosis of HIV
3. myelosuppressive chemotherapy in the previous 90 days
4. immune-modulating medications in the previous 90 days
No interventions assigned to this group
Non-Immunosuppressed
Subject does not fit immunosuppressed criteria
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged ≥18 years
* At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:
* Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)
* Heart rate greater than 90 beats per minute
* Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg
* WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms)
Exclusion Criteria
* Survival expected to be \< 7 days from positive blood cultures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Hospital
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-0491
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.